1. Home
  2. AIN vs NRIX Comparison

AIN vs NRIX Comparison

Compare AIN & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Albany International Corporation

AIN

Albany International Corporation

N/A

Current Price

$57.80

Market Cap

1.5B

ML Signal

N/A

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

N/A

Current Price

$15.74

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AIN
NRIX
Founded
1895
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Textiles
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
AIN
NRIX
Price
$57.80
$15.74
Analyst Decision
Hold
Strong Buy
Analyst Count
4
13
Target Price
$60.25
$29.46
AVG Volume (30 Days)
211.6K
844.9K
Earning Date
06-01-2026
05-01-2026
Dividend Yield
1.93%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,054,132,000.00
$76,987,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$29.30
P/E Ratio
N/A
N/A
Revenue Growth
7.29
99.31
52 Week Low
$41.15
$8.18
52 Week High
$80.71
$22.50

Technical Indicators

Market Signals
Indicator
AIN
NRIX
Relative Strength Index (RSI) 37.64 42.26
Support Level $51.37 $15.62
Resistance Level $53.88 $19.98
Average True Range (ATR) 2.08 0.78
MACD -0.41 -0.03
Stochastic Oscillator 2.41 36.46

Price Performance

Historical Comparison
AIN
NRIX

About AIN Albany International Corporation

Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: